arrow
M

Marek Hus

Medical University of Lublin
H指数:23
被引数:2,300

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-world effectiveness of pegcetacoplan in individuals with paroxysmal nocturnal haemoglobinuria and suboptimal response to C5 inhibitors

pegcetacoplan在阵发性夜间血红蛋白尿症且对C5抑制剂反应不佳的患者中的真实世界有效性

2026-10-010
PRE
A Comparison of Outcomes in Patients with Secondary Acute Promyelocytic Leukemia (APL) and De Novo APL—A Case-Matched Retrospective Analysis of the Polish Adult Leukemia Group (PALG)

比较继发性急性早幼粒细胞白血病(APL)与原发APL患者的结局——波兰成人白血病组(PALG)的病例匹配回顾性分析

Cancers
IF4.4
2026-09-080
OA
Modification of Belantamab Mafodotin Dosing to Balance Efficacy and Tolerability in the DREAMM-7 and DREAMM-8 Trials

在DREAMM-7和DREAMM-8试验中调整Belantamab Mafodotin给药剂量以平衡疗效和耐受性

2025-08-070
OAAI
Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial

患者报告的结局:比较belantamab mafodotin、bortezomib和dexamethasone与daratumumab、bortezomib和dexamethasone在复发或难治性多发性骨髓瘤患者中的疗效(DREAMM-7):一项3期、开放标签、随机对照试验的结果

2025-07-150
PRE
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial

Belantamab mafodotin 联合硼替佐米和地塞米松在复发或难治性多发性骨髓瘤患者中的应用(DREAMM-7):一项全球、随机、开放标签、III期试验的更新总生存期分析

2025-07-150
PRE
Role of sclerostin in mastocytosis bone disease
2025-01-020
OAAI
Phase III COMMODORE 2 and 1 Trials: Characterization of Breakthrough Hemolysis Events in Patients with Nocturnal (PNH) Treated with Crovalimab or Eculizumab

III期COMMODORE 2和1试验:接受克罗瓦利马布或依库珠单抗治疗的阵发性夜间血红蛋白尿症(PNH)患者突破性溶血事件的表征

BLOOD
IF23.1
2024-11-050
PRE
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
2024-08-0114
PRE
Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria
2024-06-258
PRE
Predicting chemotherapy toxicity in multiple myeloma: the prognostic value of pre-treatment serum cytokine levels of interleukin-6, interleukin-8, monocyte chemoattractant protein-1, and vascular endothelial growth factor

预测多发性骨髓瘤的化疗毒性: 治疗前血清细胞因子interleukin-6,interleukin-8,单核细胞趋化蛋白-1和血管内皮生长因子水平的预后价值

2024-05-230
OAAI